Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).

Autor: Frei CR; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA., Ryan K; AstraZeneca US Medical Affairs, Gaithersburg, MD, USA., Obodozie-Ofoegbu GO; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Moore AM; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA., Teng C; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, The University of South Carolina, Columbia, SC, USA., Lucero KT; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA., Davis LD; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA., Jones XF; College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA., Nooruddin Z; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2024 Oct; Vol. 65 (10), pp. 1520-1523. Date of Electronic Publication: 2024 Jun 04.
DOI: 10.1080/10428194.2024.2360526
Databáze: MEDLINE